RAB5A and breast carcinoma: Whether clinical response to T-DM1, as measured by pCR, correlates with RAB5A RNA expression, the study clearly showed a significant correlation between RAB5A expression and breast cancer patients treated with T-DM1 (p = 0.01, LR test), which was additionally corroborated by the results of the KAMILLA clinical trial (NCT01702571) (Engebraaten et al., 2021; Wolf et al., 2022).